Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells
Lei Zhang, Yidong Li, Chaohua Hu, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review)
Yichen Tian, Yongrong Lei, Yani Wang, et al.
International Journal of Oncology (2023) Vol. 63, Iss. 5
Open Access | Times Cited: 50
Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers
Lei Zhang, Biwei Ye, Zhuo Chen, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 3, pp. 982-997
Open Access | Times Cited: 56
Current Status and Prospects of Targeted Therapy for Osteosarcoma
Zunguo Hu, Shuang Wen, Zijun Huo, et al.
Cells (2022) Vol. 11, Iss. 21, pp. 3507-3507
Open Access | Times Cited: 55
Current Status and Prospects of Clinical Treatment of Osteosarcoma
Zong-Yuan Jiang, Ji‐Bin Liu, Xiaofeng Wang, et al.
Technology in Cancer Research & Treatment (2022) Vol. 21
Open Access | Times Cited: 44
Natural products reverse cancer multidrug resistance
Jiayu Zou, Qilei Chen, Xiao-Ci Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 14
The prevention of multi-drug resistance in cancers through the application of nanotechnology-based targeted delivery systems for combination therapies involving traditional Chinese medicine
Salik Abdullah, Shreya Mukherjee, Shweta Shweta, et al.
Pharmacological Research - Modern Chinese Medicine (2024) Vol. 10, pp. 100386-100386
Open Access | Times Cited: 13
Alkaliptosis induction counteracts paclitaxel‐resistant ovarian cancer cells via ATP6V0D1‐mediated ABCB1 inhibition
Fangquan Chen, Junhao Lin, Rui Kang, et al.
Molecular Carcinogenesis (2024) Vol. 63, Iss. 8, pp. 1515-1527
Closed Access | Times Cited: 8
Tumor microenvironment diversity and plasticity in cancer multidrug resistance
Zhi Li, Peihao Yin
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188997-188997
Closed Access | Times Cited: 15
Novel insight into mitochondrial dynamin-related protein-1 as a new chemo-sensitizing target in resistant cancer cells
Samar Sami Alkafaas, Omar K. Obeid, Mustafa Ali Radwan, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107574-107574
Closed Access | Times Cited: 5
Supramolecular host-guest nanosystems for overcoming cancer drug resistance
Sha Wu, Miaomiao Yan, Minghao Liang, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 4, pp. 805-27
Open Access | Times Cited: 12
A multi-functional nano-system combining PI3K-110α/β inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency
Ruikun Lin, Lei Zhang, Biwei Ye, et al.
Cancer Letters (2023) Vol. 563, pp. 216181-216181
Closed Access | Times Cited: 11
CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions
Jin Sun Lee, Hannah Hackbart, Xiaojiang Cui, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11791-11791
Open Access | Times Cited: 11
Despicable role of epithelial–mesenchymal transition in breast cancer metastasis: Exhibiting de novo restorative regimens
Paras Famta, Saurabh Shah, Biswajit Dey, et al.
Cancer Pathogenesis and Therapy (2024) Vol. 3, Iss. 1, pp. 30-47
Open Access | Times Cited: 4
Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor
Baojie Liu, Yongzheng Lu, Ruihui Lin, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Molecular Mechanisms of Propofol‐Induced Cognitive Impairment: Suppression of Critical Hippocampal Pathways
Xiangdong Zhou, Shasha Dong, Yuhai Xu
Journal of Neurochemistry (2025) Vol. 169, Iss. 4
Closed Access
Ginsenoside Rg3 combined with near‐infrared photothermal reversal of multidrug resistance in breast cancer MCF‐7/ADR cells
Ying Chang, Qiang Fu, Zhongqi Lu, et al.
Food Science & Nutrition (2024) Vol. 12, Iss. 8, pp. 5750-5761
Open Access | Times Cited: 3
Autophagy and Multidrug Resistance in Cancer
Tejas Girish Agnihotri, Shyam Sudhakar Gomte, Vasu Peddinti, et al.
Cancer drug discovery and develogment/Cancer drug discovery and development (2024), pp. 95-127
Closed Access | Times Cited: 3
IGFBP7 regulates cell proliferation and migration through JAK/STAT pathway in gastric cancer and is regulated by DNA and RNA methylation
Wei-Lie Mo, Li-Jian Deng, Yun Cheng, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 19
Open Access | Times Cited: 3
Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance
Wenjun Meng, Li Huang, Jia‐Min Guo, et al.
Pharmaceutics (2024) Vol. 16, Iss. 12, pp. 1549-1549
Open Access | Times Cited: 3
CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, clinical trials, and Future Directions
Jin Sun Lee, Hannah Hackbart, Xiaojiang Cui, et al.
(2023)
Open Access | Times Cited: 7
Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α
Ruixia Zhao, Sinan Cheng, Xue Bai, et al.
Biotechnology Journal (2024) Vol. 19, Iss. 4
Closed Access | Times Cited: 2
Functionalized nanoparticles crossing the brain–blood barrier to target glioma cells
Yongyan Wu, Yufeng Qian, Wei Peng, et al.
PeerJ (2023) Vol. 11, pp. e15571-e15571
Open Access | Times Cited: 6
Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors
Xu Zhang, Yuxiang Wang, Xi Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 4
Plk3 Enhances Cisplatin Sensitivity of Nonsmall-Cell Lung Cancer Cells through Inhibition of the PI3K/AKT Pathway via Stabilizing PTEN
Mengshan Xu, Xiaoyun Deng, Nana Xiang, et al.
ACS Omega (2024) Vol. 9, Iss. 8, pp. 8995-9002
Open Access | Times Cited: 1
Role and recent progress of P2Y12 receptor in cancer development
Yanni Xi, Zhenya Min, Mianxue Liu, et al.
Purinergic Signalling (2024)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top